BLTE - Belite Bio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

312.2M

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

0.57%

Insider Ownership

70.98%

Institutional Own.

3.59%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tinlarebant (LBS-008) Details Dry eye disease , Macular degeneration, Age-related macular degeneration, Geographic atrophy	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tinlarebant (LBS-008) Details Stargardt disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.